Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 3/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | LOX | P28300 | 2/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144642 | 1.00 | LMNA (0.47) | LMNATSHRF2PRSS1PRSS2 | |
| SCHEMBL8303679 | 0.81 | CA2 (0.49) | TSHRL3MBTL1ALDH1A1SMN1; SMN2CA2 | |
| SCHEMBL8304804 | 0.77 | GAA (0.49) | ALDH1A1CA2GAAMAOA | |
| SCHEMBL6789519 | 0.76 | CA2 (0.45) | CA2AKR1B1CA1CA9 | |
| SCHEMBL8303252 | 0.75 | MAPT (0.41) | F2PRSS1PRSS2PRSS3ALDH1A1 | |
| SCHEMBL6784875 | 0.75 | F2 (0.39) | F2PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL6754040 | 0.75 | ALDH1A1 (0.43) | F2PRSS1PRSS2PRSS3ALDH1A1 | |
| SCHEMBL6756435 | 0.75 | CA2 (0.46) | F2PRSS1PRSS2PRSS3ALDH1A1 | |
| SCHEMBL8307296 | 0.74 | DDB1 (0.38) | ALDH1A1SMN1; SMN2CA2GAA | |
| SCHEMBL8647785 | 0.72 | MAPT (0.42) | LMNAALDH1A1SMN1; SMN2CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251153-A1 | PEPTIDES FOR THE TREATMENT OF RENAL DISORDERS | UGH PHARMA, INC. (PA) | 2022-08-11 | — | — | US | claimed |
| EP-4021480-A1 | PEPTIDES FOR THE TREATMENT OF RENAL DISORDERS | The George Washington University (US) | 2022-07-06 | — | — | EP | claimed |
| US-20260070972-A1 | MODULATORS | XOMA US LLC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070996-A1 | FORMULATIONS FOR ANTI-INSULIN RECEPTOR ANTIBODY AND USES THEREOF | REZOLUTE INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12544394-B2 | Compositions and methods for treatment of fibrosis | BAST BIOTECHNOLOGY (US) | 2026-02-10 | — | — | US | disclosed |
| US-12371488-B2 | Modulators | XOMA (US) LLC (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4526353-A2 | FORMULATIONS FOR ANTI-INSULIN RECEPTOR ANTIBODY AND USES THEREOF | Rezolute, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2025043134-A1 | HIGH CONCENTRATION FORMULATIONS FOR ANTI-INSULIN RECEPTOR ANTIBODY AND USES THEREOF | REZOLUTE, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| US-20240036046-A1 | CANCER EXAMINATION METHOD AND CANCER TREATMENT AGENT | IMAMITSUKAI MEDICAL CORPORATION (JP) | 2024-02-01 | — | — | US | disclosed |
| WO-2023225657-A2 | FORMULATIONS FOR ANTI-INSULIN RECEPTOR ANTIBODY AND USES THEREOF | REZOLUTE, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4252773-A1 | CANCER EXAMINATION METHOD AND CANCER TREATMENT AGENT | Imamitsukai Medical Corporation (JP) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023084449-A1 | DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-05-19 | — | — | WO | disclosed |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2022-08-30 | — | — | US | disclosed |
| US-20220251153-A1 | PEPTIDES FOR THE TREATMENT OF RENAL DISORDERS | UGH PHARMA, INC. (PA) | 2022-08-11 | — | — | US | disclosed |
| US-20220227857-A1 | NOVEL MODULATORS | XOMA (US) LLC | 2022-07-21 | — | — | US | disclosed |
| EP-4021480-A1 | PEPTIDES FOR THE TREATMENT OF RENAL DISORDERS | The George Washington University (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022114091-A1 | CANCER EXAMINATION METHOD AND CANCER TREATMENT AGENT | 医療法人 今光会 | 2022-06-02 | — | — | WO | disclosed |
| US-11261247-B2 | Modulators | XOMA (US) LLC (US) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070996-A1 | FORMULATIONS FOR ANTI-INSULIN RECEPTOR ANTIBODY AND USES THEREOF | INSR, IGF1R, INSRR | LMNA 4121/4885TSHR 33/4885F2 2357/4885 |
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | MME, REN, ECE1 | LMNA 1017/4885TSHR 4042/4885F2 4134/4885 |
| US-12544394-B2 | Compositions and methods for treatment of fibrosis | LIPC, LPCAT1, SREBF1 | LMNA 1101/4885TSHR 2198/4885F2 1398/4885 |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | PCSK9, PCSK7, PCSK6 | LMNA 395/4885TSHR 622/4885F2 133/4885 |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | LMNA 248/4885TSHR 1164/4885F2 132/4885 |
| US-20260070972-A1 | MODULATORS | INSR, IGF1R, IRS1 | LMNA 3551/4885TSHR 22/4885F2 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.